Deals
Sanofi, Boehringer Ingelheim Agree to $25 Billion Asset Swap
- Boehringer to get animal-health unit, pay 4.7 billion euros
- Sanofi to receive non-prescription drug operation in deal
This article is for subscribers only.
Sanofi agreed to a 22.8 billion-euro ($25.1 billion) asset swap with Germany’s Boehringer Ingelheim GmbH that will bolster the French drugmaker’s business in selling over-the-counter drugs.
The companies reached a definitive agreement after announcing exclusive negotiations in December, they said in a statement Monday. The terms are unchanged from the original announcement: Sanofi will trade its Merial animal-health business, valued at 11.4 billion euros, for Boehringer’s 6.7 billion-euro consumer-health operation. Closely held Boehringer will also pay Sanofi 4.7 billion euros in cash.